The appointment of Lynne Patton, who planned Eric Trump’s wedding, to head the Department of Housing and Urban Development’s New York office, is raising eyebrows.
jamaica senior residence housing development fund corporation
8900 van wyck expy
new york, new york, 11418
NYS Entity Status
NYS Filing Date
FEBRUARY 28, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION
2013 - JAMAICA SENIOR RESIDENCE HOUSING DEVELOPMENT FUND CORPORATION
AROUND THE WEB
- Trump Family Wedding Planner to Head New York’s Federal Housing Office
By YAMICHE ALCINDOR and J. DAVID GOODMAN - Friday Jun 16, 2017
- ‘I’d Be Hurt and Upset’: Cities Fear Trump’s Cuts to Urban Programs
By YAMICHE ALCINDOR - Friday Mar 17, 2017
President Trump’s proposed cuts to the Department of Housing and Urban Development would eliminate programs cities have used to fund things like Meals on Wheels.
- Greater Minnesota Housing Fund Launches Impact Investment Fund
By email@example.com (Matt Sinclair) - Thursday Jun 8, 2017
A public-private partnership, the new fund will support efforts to acquire and preserve affordable housing in the Twin Cities....
- Tech Diary: Rockin' Seniors
By Andy Jordan - Friday Dec 17, 2010
A new gadget called "Chord Buddy" is allowing seniors afflicted with arthritis to play the guitar. WSJ's Andy Jordan got some residents at a senior living community to rock out with it.
- Athenex IPO Raises $66M to Fund Clinical Trials for Cancer Drugs
By Frank Vinluan - Wednesday Jun 14, 2017
The IPO window is still open for clinical-stage drug companies, and Athenex is now the latest one to pass through it. The cancer drug developer raised $66 million through a public stock offering on Wednesday, funding that the company will devote mostly to a pair of cancer drugs in late-stage clinical development. Athenex priced its […]
- New York City and James Blake Resolve Excessive-Force Claim
By BENJAMIN MUELLER - Wednesday Jun 21, 2017
- Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug
By Frank Vinluan - Tuesday May 30, 2017
Protagonist Therapeutics’ work developing an inflammatory bowel disease drug that can be taken as a pill, rather than injected, now has fresh cash and the backing of a large pharmaceutical partner. Newark, CA-based Protagonist (NASDAQ: PTGX) has entered a partnership with Janssen Biotech to develop and commercialize its drug, PTG-200. Janssen is paying Protagonist $50 […]
- Ask the NY Giants: Socks with Sandals?
Tuesday Sep 15, 2015